Can the use of low-dose dopamine for treatment of acute renal failure be justified?
The use of dopamine for the prevention and treatment of acute renal failure is widespread. Its use is based on physiology suggesting selective renal vasodilation when it is infused at low dose. This article reviews the available data on the clinical use of dopamine. When used to prevent acute renal failure in high-risk treatments there is no evidence of benefit of dopamine but, given the low incidence of significant renal failure, the studies are underpowered. In treatment of acute renal failure, the quality of the data is poor. Only in one small randomised trial of moderate acute renal failure in patients with malaria was a clinically significant benefit of dopamine shown. The rest of the data, in the form of case series, showed either no benefit of dopamine or small benefits of little clinical significance. Again, these studies are of insufficient power for conclusions to be drawn as to the overall benefits and risks. We conclude that benefits of dopamine use cannot be ruled out by currently available data but its use cannot be advised until trials examining clinically important endpoints in large numbers of patients have been performed.
Burton
C J
CJ
Richard Bright Renal Unit, Southmead Hospital, Westbury-on-Trym, Bristol, UK.
Tomson
C R
CR
D058186:Acute Kidney Injury / Q000517:prevention & control*; D000818:Animals; D004195:Disease Models, Animal; D004298:Dopamine / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D014665:Vasodilator Agents / Q000008:administration & dosage* / Q000009:adverse effects
D014665:Vasodilator Agents; D004298:Dopamine